Skip to search formSkip to main contentSkip to account menu

CP-870,893

Known as: CP-870893 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Abstract A10: Soluble CD25 and C-reactive protein predict overall survival in melanoma patients receiving anti-CD40 monoclonal antibody CP-870,893 (αCD40) and anti-CTLA4 monoclonal antibody…
Purpose: Identifying baseline patient biomarkers that predict clinical outcomes to cancer immunotherapy is a major goal for the… 
2015
2015
Abstract CT137: Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma
Purpose: Combining immunostimulatory monoclonal (mAb) and checkpoint inhibition may improve response rates and overall survival… 
2015
2015
Abstract A38: Phase I study of combination immunotherapy with agonistic CD40 monoclonal antibody (mAb) CP-870,893 (αCD40) and anti-CTLA-4 antibody tremelimumab (treme) in patients with metastatic…
Purpose: Combining therapeutic activation of immune cells and checkpoint inhibition may improve response rates and overall… 
2010
2010
A phase I study of CD40 agonist monoclonal antibody (CP-870,893) with gemcitabine in pancreatic cancer.
2539 Background: CP-870,893 is a fully human CD40 agonist monoclonal antibody that activates antigen presenting cells, triggers… 
2007
2007
Gateways to clinical trials.
[111In]-DOTA-cG250, [131I]-Metuximab injection, [177Lu]-DOTA-cG250; Anatumomab mafenatox, AP-12009; BIBW-2992, Biricodar… 
Highly Cited
2006
Highly Cited
2006
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
2507 Background: The cell-surface molecule CD40 plays a critical role in activating antigen presenting cells (APC) and mediates… 
2006
2006
Development and Validation of a Quasi-Quantitative Bioassay for Neutralizing Antibodies Against CP-870,893
The human monoclonal antibody CP-870,893 is a CD40 receptor agonist currently being developed for the treatment of cancer. A… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)